Efficacy and safety of botulinum toxin injection in reducing deltoid muscle hypertrophy.


Journal

Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070

Informations de publication

Date de publication:
11 2021
Historique:
revised: 28 09 2021
received: 17 12 2020
accepted: 19 10 2021
pubmed: 23 10 2021
medline: 2 4 2022
entrez: 22 10 2021
Statut: ppublish

Résumé

With the increasing demand for body contouring, botulinum toxin (BTX) injection is being widely used off-label for muscular hypertrophy. However, to the best of our knowledge, no study has investigated the clinical efficacy of BTX type A (BTX-A) in deltoid muscle hypertrophy. This study was conducted to evaluate the efficacy and safety of intramuscular injection of BTX in reducing deltoid muscle hypertrophy. Overall, 10 patients with bilateral deltoid muscle hypertrophy were treated with an intramuscular injection of prabotulinum toxin A, with a total of 50 units [U] administered per patient. As measured by ultrasonography, the thickness of the deltoid muscles was significantly decreased at weeks 2 and 12. In addition, the clinical assessment score by blinded investigators was improved after the treatment; however, patients' satisfaction scores were relatively low. No major complications were reported. Therefore, intramuscular injection of BTX-A seems to be a candidate for novel treatment option for deltoid muscle hypertrophy. Further larger clinical studies are warranted to confirm the efficacy of BTX-A.

Identifiants

pubmed: 34676643
doi: 10.1111/dth.15168
doi:

Substances chimiques

Botulinum Toxins, Type A EC 3.4.24.69

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e15168

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

Bogari M, Tan A, Xin Y, et al. Treatment of gastrocnemius muscle hypertrophy with botulinum toxin injection followed by magnetic resonance imaging assessment and 3-dimensional evaluation. Aesthet Surg J. 2017;37(10):1146-1156.
Wanitphakdeedecha R, Ungaksornpairote C, Kaewkes A, Sathaworawong A, Vanadurongwan B, Lektrakul N. A pilot study comparing the efficacy of two formulations of botulinum toxin type A for muscular calves contouring. J Cosmet Dermatol. 2018;17(6):984-990.
Suh Y, Jeong GJ, Noh H, et al. A multicenter, randomized, open-label comparative study of prabotulinumtoxin A with two different dosages and diverse proportional injection styles for the reduction of gastrocnemius muscle hypertrophy in Asian women. Dermatol Ther. 2019;32(5):e13009.
Oh WJ, Kwon TR, Oh CT, Kim YS, Kim BJ. Clinical application of botulinum toxin a for calf hypertrophy followed by 3-dimensional computed tomography. Plast Reconstr Surg Glob Open. 2018;6(2):e1071.
Lee HJ, Lee DW, Park YH, Cha MK, Kim HS, Ha SJ. Botulinum toxin A for aesthetic contouring of enlarged medial gastrocnemius muscle. Dermatol Surg. 2004;30(6):867-871. discussion 871.
Han KH, Joo YH, Moon SE, Kim KH. Botulinum toxin A treatment for contouring of the lower leg. J Dermatolog Treat. 2006;17(4):250-254.
Guyuron B, Huddleston SW. Aesthetic indications for botulinum toxin injection. Plast Reconstr Surg. 1994;93(5):913-918.
Cheng J, Chung HJ, Friedland M, Hsu SH. Botulinum toxin injections for leg contouring in east Asians. Dermatol Surg. 2020;46(Suppl 1):S62-S70.
Cheng J, Hsu SH, McGee JS. Botulinum toxin injections for masseter reduction in east Asians. Dermatol Surg. 2019;45(4):566-572.
Kim NH, Chung JH, Park RH, Park JB. The use of botulinum toxin type A in aesthetic mandibular contouring. Plast Reconstr Surg. 2005;115(3):919-930.
To EW, Ahuja AT, Ho WS, et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg. 2001;54(3):197-200.
Kim HJ, Yum KW, Lee SS, Heo MS, Seo K. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg. 2003;29(5):484-489.

Auteurs

Sun Hye Shin (SH)

Department of Dermatology, Chung-Ang University College of Medicine, Seoul, South Korea.

Su Jung Park (SJ)

Department of Dermatology, Chung-Ang University College of Medicine, Seoul, South Korea.

Seung Hoon Yeoum (SH)

Songpajeil Orthopedic Clinic, Seoul, South Korea.

Choon Shik Youn (CS)

Yemiwon Dermatologic Clinic, Seoul, South Korea.

Kui Young Park (KY)

Department of Dermatology, Chung-Ang University College of Medicine, Seoul, South Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH